IndustryCompany release

Merck raises 2026 outlook after third-quarter sales climb 5% to $18.1bn

🇺🇸 Merck & Co., Inc. (MRK) · Thu 29 Oct 2026

Keytruda, Winrevair and Animal Health drove Merck's third-quarter growth, while the FDA accepted a priority-review filing for sacituzumab tirumotecan in advanced or recurrent endometrial cancer.

Merck & Co., known as MSD outside the US and Canada, reported worldwide sales of $18.1 billion for the third quarter of 2026, a 5% rise. The results were published on 29 October 2026.

Keytruda, including the Keytruda Qlex formulation, contributed $8.6 billion. Winrevair, the company's pulmonary arterial hypertension therapy, brought in $694 million. Animal Health was named as another growth driver.

On a GAAP basis, earnings per share were $2.04. Non-GAAP earnings per share were $2.49, a figure that includes a one-time charge of $0.12 per share linked to a licence for SciBrunch.

Merck narrowed and raised its 2026 outlook for both sales and non-GAAP earnings per share. The source summary does not give the revised ranges.

On the pipeline, the company noted that the US Food and Drug Administration has accepted a biologics licence application (BLA) for sac-TMT, granting priority review for advanced or recurrent endometrial cancer. Priority review is an FDA designation that shortens the target review timeline for therapies that could offer significant improvements in treatment.

What it means for your team

  • Regulatory teams tracking oncology filings should note the FDA's priority-review acceptance of the sac-TMT BLA in advanced or recurrent endometrial cancer.
  • Market-access teams should watch Keytruda Qlex uptake, as it is reported together with Keytruda and the two together account for $8.6 billion of quarterly sales.
  • Winrevair's $694 million quarterly sales are a data point for those following pulmonary arterial hypertension launches and payer positioning.
  • The source summary gives no decision date for the sac-TMT BLA or the revised guidance ranges; check Merck's full release for those details.

Company's press release (SEC filing): Merck & Co., Inc. ↗

Article written by VigiEye from the official source (Merck & Co., Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →